Digital Asset DirectPoolbeg Pharma identifies new RSV drug candidates
Poolbeg Pharma PLC
Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
December 22, 2022 05:47 AM Eastern Standard Time
Video
Digital Asset Direct
News ReleaseDon’t Let RSV, Flu, and Covid-19 Hijack Your Holidays
YourUpdateTV
A video accompanying this announcement is available at: https://youtu.be/v8cdWdNaAkM RSV, covid and flu are keeping kids out of school—parents out of work and unable to gather with their families. We are in the height of the Holiday travel season with sick children and now, older adults filling hospitals nationwide Flu and RSV usually circulates from late December to mid-February. But this year, an early spike in cases is resulting in markedly higher numbers of infections and hospitalizations. More importantly, RSV infections among young children and now older adults are filling many U.S. hospitals to capacity. On average, RSV leads to 58,000 hospitalizations among children under age 5 and 177,000 hospitalizations among adults 65 and older each year, according to the U.S. Centers for Disease Control and Prevention. To raise awareness about these significant concerns, Dr Emily Volk, President of the College of American Pathologists, conducted a nationwide media tour. Topics that Dr. Volk addressed included: What exactly RSV is and how it spread Why we are seeing a surge in RSV cases How someone can tell the difference between RSV, Flu, and Covid symptoms If families want to travel and be with their families, this holiday season what precautions are needed to do that safely If you want more information on testing, please visit: cdc.gov/rsv cdc.gov/flu/weekly Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com
December 21, 2022 10:09 AM Eastern Standard Time
Video
News ReleaseKeeping the Focus on Kidney Health
YourUpdateTV
The holiday season is underway, and families and friends are gathering together, it is the perfect opportunity to discuss kidney health and create a plan of action. Recently, Susan Quaggin, MD, FASN, President of the American Society of Nephrology (ASN), participated in a nationwide satellite media and radio tour to discuss kidney health and the importance of prevention and early detection. A video accompanying this announcement is available at: https://youtu.be/i5yowghTq0E More than 37 million Americans suffer from chronic kidney conditions and acute diseases that impact virtually every aspect of their lives as well as their families and communities. Kidney diseases are the ninth leading cause of death in the United States, yet 90% of people with kidney diseases are unaware that they are affected. · Prevention and early detection is key to preventing kidney failure o Those that have a family history of kidney disease, diabetes, obesity, or other health issues are at a higher risk of kidney diseases. · Older adults, people with lower incomes, and people who are Black/African American, Hispanic/Latinx, Native/Indigenous American, Native Alaskan, Asian, and Native Hawaiian or other Pacific Islander are also most at risk for kidney diseases and kidney failure. · The American Society of Nephrology is committed to serving ALL people affected by kidney diseases and kidney failure, including our most vulnerable populations. Dialysis, a therapy for those with kidney failure, has a 5-year mortality rate, which is worse than nearly all forms of cancer and requires billions of dollars annually to manage and treat. Research shows that improved treatments to slow or stop the progression of kidney diseases are critically important. We’re United 4 Kidney Health is an awareness-building initiative led by ASN and has identifed four priorities to move the nation forward from kidney diseases and failure to kidney health: 1. INTERVENE EARLIER to prevent, diagnose, coordinate care, and educate. 2. TRANSFORM TRANSPLANT and increase access to donor kidneys. 3. ACCELERATE INNOVATION and expand patient choice. 4. ACHIEVE EQUITY and eliminate disparities. For more information, visit www.asn-online.org. About Dr. Quaggin Susan E. Quaggin, MD, FASN, is the President of the American Society of Nephrology. She hails from Canada and a graduate of the University of Toronto where she completed her residency and served as chief medical resident for the University’s St. Michael’s Hospital. She completed her nephrology fellowship at the University of Toronto and Yale University, where she also undertook research and post-doctoral training. Currently the Charles Horace Mayo Professor of Medicine, Dr. Quaggin is Chief of Nephrology/Hypertension and Director of the Feinberg Cardiovascular and Renal Research Institute at Northwestern University. In addition to her position as President of ASN, Dr. Quaggin has served in many roles at the American Society of Nephrology including: Associate and Deputy Editor for the Journal of the American Society of Nephrology, Chair of Kidney Week’s Program Committee (2013), cabinet member for the ASN Foundation for Kidney Research's Securing the Future Campaign, council liaison for the Diversity and Inclusion Committee and for the Innovation and Discovery Task Force, membership on the Public Policy Board, Education Committee, and Young Investigator Award Selection Committee, the Grants Review Committee, Chair of the Awards Committee and Chair of the Diabetic Kidney Disease Collaborative (DKD-C) Task Force. About ASN Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 132 countries. For more information, visit www.asn-online.org and follow us on Facebook, Twitter, LinkedIn, and Instagram. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com
December 21, 2022 10:04 AM Eastern Standard Time
Video
News ReleaseA.I. Drug Discovery Company Syntekabio (KOSDAQ:226330.KQ) to Explore Partnerships at the J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023
Syntekabio, Inc.
Syntekabio (KOSDAQ:226330.KQ)(226330:KS), a global AI drug discovery and development company, will participate in the 41st annual J.P. Morgan Healthcare (JPM) Conference and Biotech Showcase™ 2023, which will be held concurrently. One of the largest and most informative healthcare investment symposia in the industry, the conference connects industry leaders, investors, emerging fast-growth companies, and tech innovators from around the world. Syntekabio is also open to requests for meetings and presentations via partneringONE® through Biotech Showcase. Details of the events are as follow: WHAT: JPM BIO One-on-One Partnering 2023 WHEN: January 9-12, 2023 WHERE: San Francisco Marriott Marquis (780 Mission Street | San Francisco) WHAT: Biotech Showcase™ 2023 WHEN: January 9-11, 2023; January 18-19, 2023 (Virtual) WHERE: Hilton San Francisco Union Square (333 O'Farrell Street | San Francisco) Venture capitalists invested more than $52 billion globally in therapeutic-based biotech companies from 2019 to 2021. $35 billion of that went into biotech companies with advanced platform technologies that could transform the industry, including emerging start-ups. With the latest launch of STB Cloud, Syntekabio is generating excitement in the drug discovery industry by cutting through vast swaths of data to speed the discovery and development of new drugs. Be sure to find us in San Francisco at the J.P. Morgan Healthcare Conference and Biotech Showcase events. We encourage you to schedule a time to meet with our team to discuss your product development challenges, licensing deals, potential investment, joint ventures and research, and more. For more information, contact our B/D and I/R team led by Ellie Woo at admin@syntekabiousa.com or +1 (212) 371-2544. SyntekaBio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with its U.S. operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at www.syntekabio.com/eng. Contact Details Syntekabio USA | WMSG Sabina Lee +1 201-408-5342 wgroup@wmedical.org Company Website https://www.syntekabio.com/eng
December 21, 2022 09:27 AM Eastern Standard Time
News ReleaseThis Biotech Company is Pursuing Positive Cash Flow In 2023
Agile Therapeutics, Inc.
Biotech company Agile Therapeutics Inc. (NASDAQ: AGRX) began selling its contraceptive patch in 2021, and the company is pursuing positive cash flow by the end of 2023. The Princeton, New Jersey-based company’s Twirla patch gives women the choice to not take a birth control pill every day. Instead, women can apply the patch weekly on their buttocks, lower abdomen, or upper torso, but not their breasts. About 80% choose to adhere it to their buttocks or lower abdomen, according to the company. Additionally, Twirla is the first and only birth control patch that delivers a low dose of estrogen, which puts it in line with many daily low-dose birth control pills. “We think this product can become a market leader,” Agile CEO Al Altomari said during his RHK Disruptive Growth Conference presentation on Dec. 5. Based on Agile’s third-quarter financial results, Twirla may be a viable alternative to other methods of contraception. Between the second and third quarters: Net revenue grew 43%, from $2.1 million in the second quarter to $3 million in the third quarter. Non-GAAP operational expenditures (OPEX) decreased by 19%. Twirla factory sales increased by 54%. The company had $6.1 million cash on hand as of Sept. 30. “Based on performance so far in the fourth quarter, Agile believes revenue will continue to grow and OPEX will continue to be managed at a responsible level,” Altomari said. “We are on a really great growth spurt right now,” Altomari said. “That third quarter was not a fluke. We’re not going back. We expect both the retail and non-retail side to grow.” If Agile can continue to accelerate revenue growth and maintain OPEX consistent with the past two quarters, the company can potentially begin to generate positive cash flow by the end of 2023. Agile has also expressed a desire to acquire or license another commercial women’s health product, which could potentially accelerate the timeline to generating positive cash flow. The Food and Drug Administration (FDA) approved Twirla in 2020, and Agile began selling it in 2021. Most of the company’s sales are through retailers such as CVS Health Corp. (NYSE: CVS), and it’s working on increasing its non-retail partnerships with organizations such as Planned Parenthood in the coming years. Reaching Its Audience Agile has partnered with Afaxys Inc. to help it get Twirla into college and university health centers in addition to Planned Parenthood clinics across the United States. On the retail side, it’s working with the telehealth platform Nurx to make Twirla available to its patients. Many women in Agile’s target market — women ages 18 to 24 — get their prescriptions through telehealth platforms. Nurx medical providers have prescribed contraception to more than 1 million women. “Young women typically don’t want to spend time going to see doctors or to the pharmacy so we prioritized expanding our footprint in telehealth,” Altomari said. Twirla’s connected TV (CTV) commercial is airing in five key states — California, Florida, Texas, New York, and Illinois — where 45% of women in its target demographic live. “We have an approved product that is growing and generating revenue in a multi-billion dollar market,” Altomari said. “Our job now is to continue growing Twirla, achieve positive cash flow, and deliver shareholder value.” Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Matt Riley - Head of Investor Relations & Corporate Communications mriley@agiletherapeutics.com Company Website https://agiletherapeutics.com/
December 21, 2022 09:05 AM Eastern Standard Time
News ReleaseRecent Study from Yale University Highlights the Impact of Food Sensitivities on Health
YourUpdateTV
Unlike a food allergy, which generates an immediate response and can more easily be identified and isolated from your diet (such as a peanut allergy), food sensitivities will produce a delayed reaction, and can be from a multitude of substances. As a result, they are much harder for people to detect. It's vital to know about food sensitivities that may negatively affect your health. Recently, Dr. Wajahat Mehal, Professor of Medicine and Digestive Diseases at Yale University School of Medicine, participated in a nationwide satellite media tour to discuss food sensitivities A video accompanying this announcement is available at: https://youtu.be/f12Cqq2hwsU A recent survey from That’s it. Nutrition shows that 51% of American households are impacted by food allergies or sensitivities. Many health conditions, including being overweight, migraines, rashes, arthritis, fatigue, bloating, gastrointestinal disorders, irritable bowel syndrome (IBS), Crohn’s disease and even certain respiratory conditions and skin disorders are affected by an overlooked or misunderstood food sensitivity. Nonceliac gluten sensitivity is one such example. Researchers at Yale School of Medicine conducted a landmark study showing that patients with IBS who follow individualized diets based on an Alcat food sensitivity blood test experienced significant symptom improvement. State of the art biological testing such as the Alcat test provides a cellular-based lab analysis to evaluate over 450 food substances and additives to determine which foods may be the offenders. Based on these test results a nutritionist can help you develop an individualized eating plan to best support a patient’s health For more information, visit previmedica.com About Dr. Mehal Dr. Mehal graduated from the University of Oxford Medical Sciences Division in 1989. He works in West Haven, CT and 5 other locations and specializes in Gastroenterology. Dr. Mehal is affiliated with Yale-New Haven Hospital Saint Raphael Campus. Dr. Mehal is the Director of the Yale Fatty Liver Disease Program, Yale School of Medicine and developed an integrated NAFLD program encompassing non-invasive diagnostics, staging, nutrition, weight loss medications, HCC screening and tumor board, liver transplantation and bariatric surgery. He is also the Director of the Yale Weight Loss Program, Yale School of Medicine and helped create a new program that brings all non-surgical weight loss components into a single place and include lifestyle/dietary interventions, psychological (Mindfulness training), medications, meal replacement, and endoscopic approaches (gastric balloon). Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com
December 21, 2022 06:09 AM Eastern Standard Time
Video
Digital Asset DirectGoodbody Health "leans up" the business with CBD extraction plant sale
Goodbody Health Ltd
Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
December 21, 2022 05:07 AM Eastern Standard Time
Video
News ReleaseDarioHealth Corp. (NASDAQ: DRIO) Prominently Positioned for Digital Therapeutics Consolidation
RazorPitch/DRIO
Article Highlights Transition to valued-based healthcare is driving consolidation in digital therapeutics. Dario’s clinically verified ROI to payors is lowering costs for the national healthcare sector. What is $162 billion in annual savings worth to the healthcare industry? DarioHealth Corp. (NASDAQ: DRIO) is adding contracts with self-insured employers and national health plans as Amazon and CVS vie to lead value-based, patient-centric virtual healthcare. Digital healthcare is resulting not only in better health outcomes, but also in lower costs for the national health-care sector. Dario’s user-centric multi-chronic condition platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health, providing a turn-key, one-vendor solution for payers. As Dario continues to win RFPs with the company's full suite of chronic condition management solutions to help improve overall health, the company recently noted that a new “jumbo” global employer account represents increasing penetration of the Dario platform. The global company's adoption comes after Dario demonstrated the advantages of its single, seamless experience to improve health and outcomes in a several-month pilot and exemplifies Dario's ability to penetrate some of the largest self-insured employers. The pilot program verified previous clinical studies that resulted in a 1.4-point drop in A1c among diabetic members for a $60/month fee. Based on the industry's statistical savings of $140 per month per member on a 1 point drop in A1c, Dario could save the healthcare industry $1,632 for each of the 34 million diabetics in the US alone, or a total of $56 billion annually. Including the full suite of chronic conditions, clinical studies indicate a potential $162 billion in annual savings. Race To Retail Centric Medical Services As Dario continues to land employers, health plans, and health providers in addition to strategic partners such as Sanofi (NASDAQ: SNY), some of the largest companies race to establish a retail-centric medical services care model intended to compete with physician-owned practices and some medical facility business models. Independent Kairos Policy Group noted Dario is likely to be considered a prized target in the race to first mover advantage in retail medical services. “Digital medical services are expected to play a growing role in the virtual care offering and community access model. CVS Health appears more ready to capitalize though. One company in particular, Dario Health, appears a likely M&A or strategic partner for CVS Health in 2022 as the company continues to build out the virtual care offering. If true, this would give CVS Health a clear competitive advantage in the digital medical services market over Amazon”. Sanofi, a big-brother sponsor of Dario, recently included DarioHealth as a “success” in its digital innovation partnerships. Dario’s patient-centric platform is leading the consumerization of healthcare and dominating the digital therapeutics marketplace. The Company’s success is generating significant interest from larger consolidators in patient-centric virtual healthcare, who realize that the use of technology on an increasing scale is the key to shifting to a value-based care model. Under a value-based care model, insurers and employers require providers to be more accountable for costs and patient outcomes. Access to real-time data is critical to make a Pay-for-Performance model work. A sign of the consolidation occurring in value-based care model is the $8 billion acquisition of Signify Health by CVS Health, announced on September 5, 2022. Much like Dario Health, Signify gathers the kind of data that is appealing to major players in the healthcare market. Signify gathers a tremendous amount of data on the health status and needs of the Medicare Advantage population through home-health services. Dario gathers valuable information directly from consumers via its software platform. The Company uses billions of data points annually to customize the delivery of continuous and connected support. Dario has clinically proven durable behavioral change, which results in improved healthcare outcomes and a measurable ROI for payers. In a recent article, venture capital firm Andreessen Horowitz, known for backing tech-entrepreneurs, noted that “Consumer health startups used to operate in relatively small parts of healthcare, but they now stand to improve the entire healthcare experience. Companies are starting to realize that by putting consumers first, you can earn brand loyalty and improve patient engagement, which improves outcomes and lowers costs.” “A number of trends–including insurance coverage of telemedicine, consumers footing more of healthcare costs, and a move toward value-based care where engaging consumers can lower costs–all make now the perfect time for consumer health companies to take off.” The firm made the bold claim that a consumer health tech company will become the biggest company in the world. By The Numbers Dario is delivering on its objective to sign 100 enterprise contracts by year end, which, when fully implemented, should achieve an $80-$100 MM run rate in annual recurring revenues and exceed cash flow breakeven. Dario’s has a strong balance sheet with $68 million in cash and equivalents as of June 30, 2022, and an additional $25 million of availability on an existing credit facility. Plenty of resources to fully implement the large number of recent contracts. Using traditional valuation metrics, the anticipated $60 million in ARR run rate in December 2023 compares to Dario’s market capitalization of $115 million today. The less than 2x multiple of expected forward revenues compares favorably to other SaaS model companies’ valuations of 6-10x implying a possible multifold increase in the shares. This traditional valuation methodology does not reflect the demonstrable multi-billion dollar value proposition evident in the potential savings from diabetes, let alone MSK, behavioral health, and hypertension. The value will not be missed by the largest healthcare plans looking to reduce surging healthcare costs and vying for member engagement. Q3 Financial Highlights In November, Dario Health announced Q3 results citing: Third quarter 2022 revenues of $6.6 million increased 17.3% driven by growth in B2B Nine-month year to date revenue totaled $20.8 million, a 44% increase over the first nine months of 2021. 85 signed B2B contracts to date with $61 million in total contract value We note several other key takeaways: Aetna named as the National Account contract Strategic partner Sanofi validated Dario engagement outcomes Every channel partner, Solera, Virgin Pulse, Vitality and Alliant, is bringing in customers $60 MM ARR run rate from the existing 85 contracts when fully implemented Aetna plans Dario platform rollout to members in early 2023 Conclusion DarioHealth Corp. (NASDAQ: DRIO) is well positioned and capitalized, signing significant contracts with large clients. The digital therapeutics market is being forced to consolidate with pressure from consumers to deliver healthcare on a value-based system. With Dario’s clinically verified ROI to payers lowering costs for the national healthcare sector, DRIO is clearly delivering in a high-demand market. Investors looking to capitalize on the digital health sector need to put DRIO on their radar. For more information please visit: https://www.rcafinancialpartners.com/innovators/dariohealth/ RCA Financial Partners Inc. (“RCA Financial Partners” or “we”) is a consulting and advisory firm to small public and pre-IPO data resource innovators at the critical inflection point where proven technology requires prudent financing for success. We help our clients connect with well informed investors. To learn more about RCA Financial Partners and its data resource innovators, visit www.rcafinancialpartners.com. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. RazorPitch is responsible for the production and distribution of this content. RazorPitch is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. RazorPitch authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. RazorPitch has not been compensated to produce and syndicate this content. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website. This summary report was prepared by RCA Financial Partners and distributed by RazorPitch. RCA Financial Partners is not a securities broker-dealer, an investment adviser, or a bank, and, accordingly, this report is not subject to FINRA or SEC rules regarding broker-dealer securities research, nor to the regulations to which investment advisers or banks are subject, including regulations regarding independence of written communications. RCA has been retained and compensated by the subject company of this report. This report does not constitute, and should not be construed as an independent analysis of the subject company, or as an offer to buy or sell, or a solicitation of an offer to buy or sell any security. This report is published without regard to the specific needs of any person, and it does not take into account the particular financial situation or needs of any individual. Readers should seek professional financial advice, including tax advice, before taking any investment decision. This report is based on information that we believe to be reliable, but RCA Financial Partners does not make any express or implied representation or warranty as to the completeness, reliability, or accuracy of information contained in this report, or of information used to create this report. Further important disclosures and disclaimers are available at: www.rcafinancialpartners.com/about-us/legal-disclaimer/ Contact Details RazorPitch Mark McKelvie markrmckelvie@gmail.com Company Website http://razorpitch.com
December 21, 2022 05:00 AM Eastern Standard Time
News ReleaseHow To Support Your Immune System
YourUpdateTV
It’s always the perfect time to be thinking of ways to support your immune system. Recently, Dr. Nicole Avena, consultant for Jarrow Formulas, conducted a satellite media tour to share insights on how to support the immune system, evaluate daily nutrition and balance our diets with supplements. A video accompanying this announcement is available at: https://youtu.be/u7SMiLyoH0Y With so many individuals trying to balance work, family and busy schedules, healthy habits often take a backseat. A strong immune system is one way to support overall wellness. Ideally, we would absorb optimal amounts of nutrients through a well-balanced diet — but this can sometimes be unrealistic and difficult to achieve. To support immune health, it’s important to evaluate daily nutrition and balance our diets with supplements as needed. When the immune system works optimally, it supports overall wellness. This time of year is the perfect time to be thinking of ways to support immunity, especially with more travel, holiday stress and shorter days. Jarrow Formulas is a trusted brand that has been carefully formulating supplements since 1977. Informed by scientific research, Jarrow products have the potential to support and promote health.* Here are some supplements to consider to help support your immune system, gut health, energy and overall wellness*: Methyl B-12 (methylcobalamin) supports brain and nerve health and function, cellular energy production and sleep-wake cycles.* Methylcobalamin is a biologically active form of B12 that is better retained than cyanocobalamin.* It can be beneficial to vitamin B12 deficient people, especially some seniors and vegetarians/vegans (as plant-based diets can cause vitamin B12 deficiencies).* N-A-C or N-Acetyl-L-Cysteine is a powerful antioxidant amino acid and a precursor in the body to the critical antioxidant glutathione.* It supplies readily available L-cysteine, which acts as an antioxidant itself or as a precursor to glutathione.* Glutathione is essential for the immune system’s proper functioning, is vital in maintaining healthy tissue and supports liver function.* Immune Booster is a convenient and effective product to have on hand. It includes not one, but two, clinically studied and supported ingredients (a prebiotic and a probiotic strain) to create an easy and convenient way, to support a healthy immune system.* Just one single-serve packet per day helps maintain a healthy immune system, normal digestion and regularity.* Jarro-Dophilus EPS ® is a shelf stable probiotic supplement that features an enteric coating to protect the probiotic strains from stomach acid. Eight different strains of probiotic bacteria are delivered directly into the small intestines where probiotic bacteria fully exert their beneficial effects.* Those seeking to support their intestinal tract health may benefit from using the Jarro-Dophilus EPS ® probiotic supplement.* To learn more, and to find supplements to fit your diet and lifestyle, visit Jarrow.com About Jarrow Formulas Jarrow Formulas ® was founded in 1977 in Los Angeles with the goal to promote optimal health with high-quality, effective, affordable and superior formulation of dietary supplements. Jarrow offers a wide range of scientifically supported supplements including products that support digestive, bone, brain, heart and immune health, and supplements that aid with energy and metabolism.* Jarrow Formulas products are available worldwide in countries throughout North America, Europe, Asia, Latin America and the Middle East. About Vytalogy Wellness Every day, Vytalogy and its family of brands, Natrol and Jarrow Formulas, bring a vibrant energy to life. Vytalogy Wellness' mission is to be a modern wellness company that fuses science and quality ingredients to create highly efficacious products that make a transformative impact on consumers' lives. Based in California with more than 600 employees, Vytalogy markets products across multiple channels and many supplement categories. Vytalogy is a portfolio company of New Mountain Capital, LLC. Visit Vytalogy Wellness for more information. About Dr. Nicole Avena Dr. Nicole Avena is a research neuroscientist and a pioneer in the field of food addiction. Her seminal research work jump-started a new field of exploration in medicine and nutrition. She is an expert in diet during pregnancy and baby, toddler and childhood nutrition. She received a Ph.D. in Neuroscience and Psychology from Princeton University, followed by a postdoctoral fellowship in molecular biology at The Rockefeller University in New York City. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com
December 20, 2022 12:11 PM Eastern Standard Time
Video